Results 71 to 80 of about 169,093 (102)

Familial Chylomicronaemia Syndrome (FCS) Score Validation in United Kingdom FCS Registry: Can Additional Variables Improve the FCS Score Performance?

open access: yesAtherosclerosis Plus, 2023
B. Bashir   +20 more
doaj   +1 more source

A cross-sector, multidisciplinary approach to lipid optimisation

open access: yesAtherosclerosis Plus, 2023
M. Jones   +8 more
doaj   +1 more source

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia

open access: yesAtherosclerosis Plus, 2023
E. Ofagbor   +4 more
doaj   +1 more source

A Call to Leadership: New VTE Treatment and Prevention Guidelines

open access: yesClinical and Applied Thrombosis/Hemostasis
Omar L. Esponda MD   +1 more
doaj   +1 more source

Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: The importance of differentiation grade in determining treatment strategy.

open access: yesOral Oncology, 2016
T. P. van der Laan   +5 more
semanticscholar   +1 more source

Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease

open access: yesJournal of Pharmacology and Experimental Therapeutics, 2017
Jeff W. Peng   +9 more
semanticscholar   +1 more source

Evaluation of the Cobas u 701 microscopy analyser compared with urine culture in screening for urinary tract infection

open access: yesJournal of Medical Microbiology, 2017
S. Kim   +7 more
semanticscholar   +1 more source

Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM).

open access: yesAnnals of Oncology, 2018
D. Peereboom   +19 more
semanticscholar   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Tern-701 (HS-10382) Is a Potent Inhibitor of BCR::ABL1 and Is Synergistic with Active Site Tyrosine Kinase Inhibitors

Blood, 2023
Although tyrosine kinase inhibitors (TKIs) targeting the ATP-binding site of the BCR::ABL1 oncoprotein are effective therapeutics for chronic myeloid leukemia (CML), patients often develop drug resistance due to ATP-site mutations that inhibit drug ...
Benjamin M Parsons   +2 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy